Ney Carter Borges on Colchicine As 2ry Prevention in Atherosclerotic CVD
Ney Carter Borges, Member Cardiologist of Global Physician Association at Cleveland Clinic Florida, shared on LinkedIn:
”Low-dose colchicine (0.5 mg/day) has emerged as an effective anti-inflammatory strategy for secondary prevention in atherosclerotic cardiovascular disease.
By inhibiting microtubule assembly, colchicine suppresses activation of the NLRP3 inflammasome, leading to reduced interleukin-1β and interleukin-6 signaling, key drivers of plaque inflammation and instability.
Clinical trial data demonstrate that colchicine significantly stabilizes atherosclerotic plaques, attenuates neutrophil activation, and reduces thrombogenic potential.
A pooled analysis of randomized trials shows a 25% relative reduction in major adverse cardiovascular events (HR ~0.75), with consistent reductions in myocardial infarction (≈23%), ischemic stroke (≈22%), and cardiovascular mortality (≈34%).
These benefits occur without an increase in non-cardiovascular mortality and with good tolerability in most patients.
Taken together, these findings position colchicine as a third pillar of secondary prevention, complementing lipid-lowering and antithrombotic therapies by targeting residual inflammatory risk in patients with established atherosclerosis.”
Stay updated with Hemostasis Today.
-
Sep 13, 2026, 14:37Mohammad Zamrood Khan: Hereditary Spherocytosis and Protein C/S Deficiency Case Report Submitted
-
Sep 13, 2026, 14:33Heghine Khachatryan: A Resource-Adapted Approach to Hemophilia Joint Care
-
Sep 13, 2026, 14:23Simon Fletcher: The Unmet Burden of Factor VII Deficiency
-
Sep 13, 2026, 14:10Azusa Nagao: The Evolving Burden of Haemophilia Prophylaxis
-
Sep 13, 2026, 13:50Priya Sriskandarajah: The Challenge of Thrombotic Risk in Myeloproliferative Neoplasms
-
Sep 13, 2026, 12:31Vishakha K. Kumar: ISTH Opens Public Comment Period on New Guidance
-
Sep 13, 2026, 12:13Tahsin Ara Mim: Takayasu’s Arteritis Case Report Secures 2nd Runner-Up
-
Sep 13, 2026, 11:26Tareq Abadl: When Good Samples Give Bad Numbers – Spotting EDTA Contamination in the Lab
-
Sep 13, 2026, 11:22Amanda Unsworth: Gratitude and Next Steps as Leadership Transitions at The Platelet Society